Abstract
Purpose.:
We evaluated the prevalence and risk factors for diabetic retinopathy (DR) in a representative Korean population.
Methods.:
This cross-sectional study involved 16,109 subjects aged >40 years who had participated in the Korean National Health and Nutrition Survey from 2008 to 2011. Seven standard retinal fundus photographs were obtained after pupil dilatation from both eyes. The DR was graded using the modified Airlie House classification system. Risk factors for DR and vision-threatening diabetic retinopathy (VTDR) were evaluated, including age, sex, diabetes duration, glycated hemoglobin (HbA1c), hypertension, lipid profiles, and refractive error.
Results.:
Of the 16,109 eligible individuals participating in the study, 14,595 (90.6%) had fasting blood glucose results available. Of these, 2023 (13.8%) were diagnosed with diabetes mellitus. Among these, gradable photographs were available for 1678 subjects (82.9%), including 1323 subjects with known diabetes mellitus (KDM) and 355 with newly diagnosed diabetes mellitus (NDM). The prevalences of any DR and VTDR were 15.8% (95% confidence interval [CI], 14.1–17.5), and 4.6% (95% CI, 3.6–5.6), respectively. Any DR was associated with a longer duration of diabetes (odds ratio [OR], 1.08; 95% CI, 1.06–1.10), higher HbA1C level (OR, 1.52; 95% CI, 1.28–1.80), higher systolic blood pressure (OR, 1.02; 95% CI, 1.01–1.03), and lower body mass index (OR, 0.91; 95% CI, 0.87–0.96) in a multivariate analysis.
Conclusions.:
We provide data on the prevalence and risk factors for DR in a representative Korean population. The prevalence of any DR and VTDR in the Korean population was lower than that reported previously. The condition of DR was associated with a longer duration of diabetes, poor glycemic control, and higher systemic blood pressure.
This study was based on data acquired in the Korea National Health and Nutrition Survey (KNHNS), 2008 to 2011. The KNHNS is an ongoing, population-based, cross-sectional, and nationally representative survey conducted by the Division of Chronic Disease Surveillance, Korean Center for Disease Control and Prevention. The survey consisted of a health interview, a nutritional survey, and a health examination survey. The survey collected data via household interviews and by direct standardized physical examinations conducted in a specially-equipped mobile examination center. The sample design and size are estimated by KNHNS, so the results can be generalized to the entire Korean population.
Annually, 4000 households in 200 enumeration districts were selected by a panel to represent the civilian, noninstitutionalized South Korean population using the systemic stratified, multistage clustered sampling method based on the National Census Data. All members of each selected household were asked to participate in the survey, and a participation rate between 2008 and 2011 ranged from 77.8% to 82.8%.
All participants provided informed consent. This study design followed the tenets of the Declaration of Helsinki for biomedical research and was approved by the Institutional Review Board of the Catholic University of Korea, Seoul, Korea.
Participants were considered to have type 1 DM if they were aged <30 years when diagnosed with DM and were receiving insulin therapy.
13 Otherwise, DM was considered type 2. Those who were diagnosed by a self-reported history of a physician diagnosis or those who were receiving drug treatment for DM, including insulin or oral hypoglycemic agents, were classified as subjects with known diabetes mellitus (KDM), while those who had a fasting plasma glucose level > 126 mg/dL without a previous diagnosis of DM were classified as subjects with new diabetes mellitus (NDM).
13
In participants with a history of DM, random blood glucose level > 200 mg/dL, or a suspicious diabetic DR finding in nonmydriatic 45° digital fundus photographs (TRC-NW6S; Topcon, Tokyo, Japan), which was performed in all participants > 40 years old, seven standard photographs from the Early Treatment for Diabetic Retinopathy Study (ETDRS) were obtained from both eyes after pharmacologic pupil dilatation.
Retinopathy was identified if any characteristic lesion as defined by the ETDRS severity scale was present: microaneurysms (MAs), hemorrhages, cotton wool spots (CWSs), intraretinal microvascular abnormalities (IRMAs), hard exudates (HEs), venous beading, and new vessels. A retinopathy severity score was assigned to each eye according to the modification of the Airlie House Classification system as follows
14 : Level 10, no retinopathy present; level 14, any combination of definite HE, CWS, IRMA, or venous loops in the absence of definite MA; level 15, hemorrhage present without any definite MA; level 20, MA only with no other diabetic lesion present; level 31, MA and one or more of the following: hemorrhage or MA less than standard photograph 2A, HE, venous loops, questionable CWS, IRMA, or venous beading; level 41, MA and one or more of the following: CWS, IRMA less than standard photograph 8A; level 51, MA and one or more of the following: venous beading, hemorrhage or MA > 2A, IRMA > 8A; level 60, fibrous proliferation with no other proliferative lesions; levels 61 to 64, laser scatter photocoagulation scars with retinopathy levels 31 to 51; level 65, proliferative DR less than high-risk characteristics, as defined in the Diabetic Retinopathy Study; level 70, proliferative DR with more than high risk characteristics; and level 80, total vitreous hemorrhage.
The level of retinopathy was graded based on the worse eye. Eyes were graded according to the following criteria: no DR (levels 10–13) or any DR (levels 14–80). The DR was divided further into minimal nonproliferative DR (NPDR, levels 14–20), mild NPDR (level 31), moderate NPDR (levels 41–47), severe NPDR (level 51), and proliferative DR (level > 60).
The condition of ME was defined by HE in the presence of MA and blot hemorrhage within one disk diameter from the foveal center, or the presence of focal photocoagulation scars in the macular area. Clinically significant ME (CSME) was considered present when the ME involved or was within 500 μm of the foveal center, or if focal photocoagulation scars were present in the ME. The VTDR was defined as the presence of severe NPDR, proliferative retinopathy, or CSME.
14
Various associated factors were examined. Blood pressure (BP) was measured by standard methods using a sphygmomanometer with the patient in a sitting position. Three measurements were made in all subjects at 5-minute intervals, and the average of the second and third measurements was used in the analysis. Blood samples were collected in the morning after fasting for at least 8 hours. Fasting glucose, glycated hemoglobin (HbA1c), total cholesterol, triglycerides, low-density lipoprotein, cholesterol, and vitamin D levels were measured at a central, certified laboratory. The presence of DM was defined as fasting glucose > 126 mg/dL or if the individual was prescribed antiglycemic medication. The presence of hypertension was defined as a systolic BP >140 mm Hg or diastolic BP > 90 mm Hg, or if the individual was prescribed antihypertensive medication. Hypercholesterolemia was defined as a total cholesterol concentration > 240 mg/dL or if the individual was prescribed anticholesterol medication. Heart problems were defined as a history of myocardial infarction (MI) or angina. Refractive errors was defined as myopia (<−1.0 diopters [D]) and hyperopia (>+1.0 D). Body mass index (BMI) was calculated by dividing body weight by height squared (kg/m2) after height and weight were measured using standardized techniques and equipment. Obesity was defined as a BMI > 25 kg/m2. Information regarding demographic and social factors was obtained using a standardized questionnaire during a health interview.
Of the 16,109 eligible participants, 14,595 (90.6%) completed the fasting plasma glucose examination. Among the subjects with fasting plasma glucose results, 2023 (13.8%) subjects met the criteria for DM. Of these, 1678 (82.9%) participants had seven gradable standard photographs.
The characteristics of the study population are shown in
Table 1. Compared to nondiabetic subjects, patients with DM were more likely to be older, male, and have higher serum glucose, higher systolic BP, and higher total cholesterol, but less likely to drink alcohol. Among participants with DM, 6.7% reported previous angina or MI and 5.8% reported a previous stroke.
Table 1 Characteristics of Participants in the Korean National Health and Nutrition Examination Survey, 2008 to 2011
Table 1 Characteristics of Participants in the Korean National Health and Nutrition Examination Survey, 2008 to 2011
Characteristics | No Diabetes, n = 12,572 | Diabetes, n = 2023 | P | Participants, n = 14,595 | Nonparticipants, n = 1514 | P |
Age, per y | 57.2 ± 11.6 | 63.1 ± 10.2 | <0.001 | 58.0 ± 11.6 | 64.1 ± 13.8 | <0.001 |
Sex, male | 42.5 | 50.9 | <0.001 | 43.7 | 38.3 | <0.001 |
Fasting glucose, mg/dL | 94.5 ± 9.6 | 141.2 ± 45.5 | <0.001 | 101.0 ± 25.0 | NA | NA |
HbA1c, % | 5.7 ± 0.4 | 7.3 ± 1.4 | <0.001 | 6.2 ± 1.2 | NA | NA |
Systolic BP, mm Hg | 122.9 ± 17.6 | 129.1 ± 17.4 | <0.001 | 123.8 ± 17.7 | 126.3 ± 19.5 | <0.001 |
Diastolic BP, mm Hg | 78.1 ± 10.5 | 77.1 ± 10.4 | <0.001 | 78.0 ± 10.5 | 75.8 ± 11.3 | <0.001 |
Hypertension | 39.0 | 63.8 | <0.001 | 42.5 | 50.7 | <0.001 |
Total cholesterol, mg/dL | 194.2 ± 35.7 | 188.3 ± 41.1 | <0.001 | 193.4 ± 36.6 | NA | NA |
Triglyceride, mg/dL | 137.4 ± 101.3 | 177.5 ± 140.7 | <0.001 | 142.9 ± 108.5 | NA | NA |
Hypercholesterolemia | 15.2 | 26.9 | <0.001 | 16.8 | NA | NA |
Hyperlipidemia | 16.1 | 27.1 | <0.001 | 17.6 | NA | NA |
Angina or MI | 3.0 | 6.7 | <0.001 | 3.5 | 5.7 | <0.001 |
Previous stroke | 2.4 | 5.8 | <0.001 | 2.9 | 5.0 | <0.001 |
Creatinine, mg/dL | 0.82 ± 0.2 | 0.89 ± 0.4 | <0.001 | 0.83 ± 0.2 | NA | NA |
Refractive error, D | −0.33 ± 1.9 | −0.07 ± 1.7 | <0.001 | −0.29 ± 1.8 | −0.01 ± 1.7 | <0.001 |
Myopia, present vs. absent | 34.1 | 30.4 | <0.001 | 33.6 | 32.1 | 0.255 |
Hyperopia, present vs. absent | 23.8 | 30.8 | <0.001 | 24.8 | 31.8 | <0.001 |
BMI, kg/m2 | 23.8 ± 3.0 | 24.9 ± 3.3 | <0.001 | 23.9 ± 3.1 | 23.3 ± 3.5 | <0.001 |
Obesity, present vs. absent | 32.8 | 47.3 | <0.001 | 34.8 | 31.5 | 0.013 |
Alcohol drinking | 81.7 | 77.8 | <0.001 | 81.2 | 73.9 | <0.001 |
Current smoking | 18.6 | 20.2 | 0.062 | 18.8 | 21.0 | 0.069 |
Ever smoking | 40.3 | 48.2 | <0.001 | 41.4 | 43.3 | 0.205 |
Vitamin D, ng/mL | 19.3 ± 6.9 | 19.4 ± 7.1 | 0.809 | 19.3 ± 6.9 | NA | NA |
A total of 1323 subjects (78.8%) reported that they had been diagnosed previously with DM (KDM), including 33 treated with only diet or exercise without medication, 1164 treated with oral hypoglycemic agents, 41 treated with insulin, and 85 treated with a combination of insulin and oral hypoglycemic agents, whereas 355 subjects (21.2%) were assigned to the NDM group. Type 1 DM occurred in only eight patients (0.4%) among those with DM > 40 years old.
The prevalence of any DR in Koreans was 15.8% (95% CI, 14.1–17.5) in those 40+ years (
Table 2). Of those aged 40+ years, VTDR was present in 4.6% (95% CI, 3.6–5.6) and CSME in 1.6% (95% CI, 1.0–2.2). The prevalence of any DR increased with age from those aged 40 to 49 years to those aged 60–69 years, and then decreased in those aged ≥70 years (
P = 0.123). The prevalence of any DR was not different between males (15.4%) and females (16.2%) with DM (
P = 0.639).
Table 2 Prevalence and Severity of DR and ME According to Age and Sex in the Korean National Health and Nutrition Examination Survey, 2008 to 2011
Table 2 Prevalence and Severity of DR and ME According to Age and Sex in the Korean National Health and Nutrition Examination Survey, 2008 to 2011
| Sex, n (%, 95% CI) | Age Groups, n (%, 95% CI) |
Total, n = 1678 | Male, n = 839 | Female, n = 839 | P | 40–49 y, n = 215 | 50–59 y, n = 410 | 60–69 y, n = 588 | 70 + y, n = 465 | P |
Any DR | 265 (15.8, 14.1–17.5) | 129 (15.4, 13.0–17.8) | 136 (16.2, 13.7–18.6) | 0.639 | 22 (10.2, 6.2–14.2) | 64 (15.6, 12.1–19.1) | 108 (18.4, 15.3–21.5) | 71 (15.3, 12.0–18.6) | 0.123 |
DR grades |
Minimal | 114 (6.8, 5.5–8.0) | 58 (6.9, 5.2–8.6) | 56 (6.7, 5.0–8.4) | 0.616 | 8 (3.7, 1.2–6.2) | 26 (6.3, 3.9–8.7) | 46 (7.8, 5.6–10.0) | 34 (7.3, 4.9–9.7) | 0.576 |
Mild | 68 (4.1, 3.2–5.0) | 29 (3.5, 2.3–4.7) | 39 (4.6, 3.2–6.0) | 7 (3.3, 0.9–5.7) | 12 (2.9, 1.3–4.5) | 33 (5.6, 3.7–7.5) | 16 (3.4, 1.8–5.0) |
Moderate | 23 (1.4, 0.8–1.9) | 14 (1.7, 0.8–2.5) | 9 (1.1, 0.4–1.8) | 2 (0.9, 0–2.2) | 7 (1.7, 0.4–3.0) | 8 (1.4, 0.5–2.3) | 6 (1.3, 0.3–2.3) |
Severe | 14 (0.8, 0.4–1.2) | 6 (0.7, 0.1–1.2) | 8 (1.0, 0.3–1.7) | 1 (0.5, 0–1.4) | 4 (1.0, 0.0–2.0) | 4 (0.7, 0.0–1.4) | 5 (1.1, 0.2–2.0) |
Proliferative | 46 (2.7, 1.9–3.4) | 22 (2.6, 1.5–3.6) | 24 (2.9, 1.7–4.0) | 4 (1.9, 0.1–3.7) | 15 (3.7, 1.9–5.5) | 17 (2.9, 1.5–4.3) | 10 (2.2, 0.9–3.5) |
ME | 48 (2.8, 1.2–3.8) | 26 (3.1, 1.9–4.3) | 22 (2.6, 1.5–3.7) | 0.660 | 6 (2.8, 0.6–5.0) | 14 (3.4, 1.6–5.2) | 12 (2.0, 0.9–3.1) | 16 (3.4, 1.8–5.0) | 0.915 |
CSME | 27 (1.6, 1.0–2.2) | 15 (1.8, 0.9–2.7) | 12 (1.4, 0.6–2.1) | 0.561 | 4 (1.9, 0.1–3.7) | 8 (2.0, 0.6–3.4) | 6 (1.0, 0.2–1.8) | 9 (1.9, 0.7–3.1) | 0.850 |
VTDR | 77 (4.6, 3.6–5.6) | 37 (4.4, 3.0–5.7) | 40 (4.8, 3.4–6.2) | 0.726 | 7 (3.3, 0.9–5.7) | 25 (6.1, 3.8–8.4) | 25 (4.3, 2.7–5.9) | 20 (4.3, 2.5–6.1) | 0.833 |
The presence and severity of DR were associated strongly with DM duration (see
Figure). The prevalence of any DR in the NDM group was 2.8%, whereas the prevalence in those with a diabetes history ≥ 10 years was 33.2% (
P < 0.001). Similarly, the prevalence of VTDR was significantly higher in those with DM for ≥10 years (12.5%) compared to NDM subjects (0.3%,
P < 0.001).
The prevalence of any DR was higher in the KDM group (19.3%) than in the NDM group (2.8%,
P < 0.001,
Table 3). Subjects with KDM had a higher frequency of all grades of retinopathy than did those with NDM (
P < 0.001). The prevalence of VTDR was 5.8% in KDM and 0.3% in NDM (
P < 0.001).
Table 3 Prevalence of DR in Those With Known DM and NDM in the Korean National Health and Nutrition Examination Survey, 2008 to 2011
Table 3 Prevalence of DR in Those With Known DM and NDM in the Korean National Health and Nutrition Examination Survey, 2008 to 2011
| n (%, 95% CI) |
Total, n = 1678 (%) | NDM, n = 355, 21.2% | KDM, n = 1323, 78.8% | P |
Any DR | 265 (15.8) | 10 (2.8, 1.1–4.5) | 255 (19.3, 17.2–21.4) | <0.001 |
DR grades |
Minimal DR | 114 (6.8) | 6 (1.7, 0.4–3.0) | 108 (8.2, 6.7–9.7) | <0.001 |
Mild DR | 68 (4.1) | 2 (0.6, 0–1.4) | 66 (5.0, 3.8–6.2) |
Moderate DR | 23 (1.4) | 1 (0.3, 0–2.6) | 22 (1.7, 1.0–2.4) |
Severe NPDR | 14 (0.8) | 1 (0.3, 0–0.9) | 13 (1.0, 0.5–1.5) |
PDR | 46 (2.8) | 0 (0) | 46 (3.5, 2.5–4.5) |
ME | 48 (2.8) | 6 (1.7, 0.4–3.0) | 42 (3.2, 2.3–4.1) | 0.136 |
CSME | 27 (1.4) | 0 (0) | 27 (2.1, 1.3–2.9) | 0.007 |
VTDR | 77 (4.6) | 1 (0.3, 0–0.9) | 76 (5.8, 4.5–7.1) | <0.001 |
The association between various risk factors and either any DR or VTDR is shown in
Table 4. In a multivariate analysis, independent risk factors for any DR were longer DM duration (OR, 1.08 per year increase), higher HbA1c (OR, 1.52 per 1% increase), higher systolic BP (OR, 1.02 per 1 mm Hg increase), higher creatinine (OR, 2.65 per 1 mg/dL increase), and lower BMI (OR, 0.91 per 1 unit). Similarly, VTDR was associated with longer DM duration (OR, 1.09 per year increase), higher HbA1c (OR, 1.64 per 1% increase), higher systolic BP (OR, 1.03 per 1 mm Hg increase), higher creatinine (OR, 2.33 per 1 mg/dL increase), and lower BMI (OR, 0.88 per 1 unit).
Table 4 Risk Factors for DR and VTDR in the Korean National Health and Nutrition Examination Survey, 2008 to 2011
Table 4 Risk Factors for DR and VTDR in the Korean National Health and Nutrition Examination Survey, 2008 to 2011
Characteristics | Any Diabetic Retinopathy | Vision-Threatening Diabetic Retinopathy |
Age–Sex Adjusted OR | P | Multivariate OR | P | Age–Sex Adjusted OR | P | Multivariate OR | P |
Age, per y | 1.01 (0.99–1.02) | 0.148 | 0.97 (0.95–0.99) | 0.021 | 1.00 (0.97–1.02) | 0.913 | 0.93 (0.90–0.97) | 0.003 |
Sex, female | 1.04 (0.79–1.35) | 0.797 | 1.21 (0.67–2.17) | 0.533 | 1.09 (0.97–1.02) | 0.872 | 3.31 (1.07–10.18) | 0.037 |
Diabetes duration, y | 1.10 (1.08–1.12) | <0.001 | 1.08 (1.06–1.10) | <0.001 | 1.13 (1.10–1.16) | <0.001 | 1.09 (1.05–1.13) | <0.001 |
Fasting glucose, mg/dL | 1.01 (1.01–1.01) | <0.001 | 0.99 (0.99–1.00) | 0.854 | 1.01 (1.01–1.01) | <0.001 | 0.99 (0.98–1.01) | 0.688 |
HbA1c, % | 1.57 (1.44–1.71) | <0.001 | 1.52 (1.28–1.80) | <0.001 | 1.57 (1.39–1.77) | <0.001 | 1.64 (1.24–2.18) | <0.001 |
Systolic BP, mm Hg | 1.00 (0.99–1.01) | 0.591 | 1.02 (1.01–1.03) | 0.002 | 1.00 (0.98–1.01) | 0.529 | 1.03 (1.00–1.05) | 0.027 |
Diastolic BP, mm Hg | 0.96 (0.96–0.98) | <0.001 | 0.97 (0.94–0.99) | 0.002 | 0.95 (0.93–0.97) | <0.001 | 0.96 (0.92–1.01) | 0.97 |
Hypertension* | 0.79 (0.60–1.04) | 0.090 | 0.88 (0.58–1.33) | 0.546 | 0.64 (0.40–1.03) | 0.067 | 0.59 (0.27–1.32) | 0.206 |
Total cholesterol, mg/dL | 1.00 (0.99–1.01) | 0.392 | 1.00 (0.99–1.01) | 0.603 | 0.99 (0.99–1.00) | 0.274 | 0.99 (0.98–1.00) | 0.114 |
Triglyceride, mg/dL | 1.00 (1.00–1.00) | 0.096 | 1.00 (1.00–1.00) | 0.073 | 1.00 (0.99–1.00) | 0.424 | 1.00 (1.00–1.00) | 0.101 |
Hypercholesterolemia* | 1.24 (0.92–1.66) | 0.157 | 1.13 (0.76–1.66) | 0.543 | 1.29 (0.78–2.13) | 0.307 | 1.36 (0.68–2.72) | 0.379 |
Angina or MI* | 1.16 (0.71–1.91) | 0.543 | 1.07 (0.55–2.10) | 0.830 | 1.15 (0.48–2.73) | 0.743 | 1.06 (0.31–3.74) | 0.918 |
Previous stroke* | 1.31 (0.76–2.25) | 0.330 | 0.88 (0.43–1.84) | 0.744 | 1.57 (0.65–3.78) | 0.309 | 1.39 (0.37–5.12) | 0.616 |
Creatinine, mg/dL | 2.53 (1.512–4.26) | <0.001 | 2.65 (1.34–5.25) | 0.005 | 3.34 (1.63–6.85) | <0.001 | 2.33 (1.03–5.31) | 0.043 |
Myopia* | 0.97 (0.72–1.32) | 0.882 | 1.15 (0.70–1.88) | 0.575 | 1.79 (1.09–2.96) | 0.022 | 1.81 (0.76–4.32) | 0.178 |
Hyperopia* | 0.91 (0.67–1.24) | 0.538 | 0.74 (0.46–1.19) | 0.214 | 0.75 (0.41–1.35) | 0.343 | 0.62 (0.24–1.58) | 0.325 |
BMI, kg/m2 | 0.90 (0.86–0.94) | <0.001 | 0.91 (0.87–0.96) | 0.001 | 0.84 (0.78–0.90) | <0.001 | 0.88 (0.80–0.96) | 0.009 |
Alcohol drinking* | 0.96 (0.68–1.36) | 0.824 | 1.24 (0.79–1.93) | 0.342 | 0.71 (0.40–1.26) | 0.250 | 0.70 (0.32–1.52) | 0.373 |
Current smoker* | 1.23 (0.86–1.75) | 0.251 | 1.18 (0.71–1.97) | 0.509 | 1.44 (0.79–2.62) | 0.227 | 1.34 (0.53–3.39) | 0.530 |
Ever smoker* | 1.07 (0.71–1.61) | 0.751 | 0.82 (0.45–1.51) | 0.535 | 1.21 (0.59–2.48) | 0.602 | 1.80 (0.56–5.75) | 0.319 |
Vitamin D, ng/mL | 0.99 (0.97–1.01) | 0.314 | 1.00 (0.98–1.03) | 0.725 | 1.00 (0.96–1.03) | 0.748 | 1.03 (0.98–1.07) | 0.206 |